Top Markets
Coin of the day
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Rang in Aktien #16730
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Aktienkurs
$3.78
Zuletzt synchronisiert: 2026-03-17
Marktkapitalisierung
$276.54M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
45.53%
Land
CA
Handel NervGen Pharma Corp. (NGEN)

Kategorie

Kursverlauf für NervGen Pharma Corp. (NGEN)
Höchster Schlusskurs: $3.98 am 2026-03-01

Niedrigster Schlusskurs: $1.12 am 2019-03-01
Kursverlauf der Aktie von NervGen Pharma Corp. von 2019 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -18.31%
2025 129.35%
2024 42.00%
2023 15.06%
2022 -43.93%
2021 48.46%
2020 21.58%
2019 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$548.15 36.70%
US
$1.03K 45.33%
NL
$153.87 536.09%
US
$122.24 -10.01%
AU
$748.60 6.90%
CH